There have been major advancements in the fight against tuberculosis (TB), including the implementation of rapid molecular diagnostic tests, new drugs \[[@CIT0001]\], shorter regimens for drug-resistant disease, and, most recently in September 2018, the first ever United Nations high-level meeting on TB \[[@CIT0002]\]. However, despite modest progress, TB has emerged as the leading cause of death due to an infectious disease. TB/HIV coinfection is one of the major challenges of global TB control, and TB remains the leading cause of mortality among people living with HIV (PLWH). There remains large gaps in both the detection and treatment of HIV-associated TB; out of the almost 1 million new cases of TB among PLWH in 2017, only half were diagnosed and reported \[[@CIT0002]\]. Many PLWH with TB disease may not present to care until late in their disease course, as TB disease in this population typically manifests with nonspecific symptoms or can be asymptomatic \[[@CIT0003]\]. Even after presenting at a health facility, confirmatory diagnosis of TB in PLWH is difficult due to nonspecific symptoms, atypical chest radiography, and a higher prevalence of sputum-smear negative disease \[[@CIT0003]\].

Globally, TB accounts for one-third of all HIV-related deaths, with a diverging pattern seen in Europe. TB-related HIV-mortality in Eastern Europe (EE) is 27%, which is in contrast to the rest of Europe (\<10%) \[[@CIT0003], [@CIT0006], [@CIT0007]\]. Specifically, in the country of Georgia, TB remains the leading cause of death in PLWH \[[@CIT0008]\]. A combination of factors, including increasing HIV prevalence and drug-resistant TB, high rates of late HIV diagnosis, and overlapping risk factors for TB and HIV, makes Georgia particularly vulnerable to a TB/HIV epidemic \[[@CIT0006], [@CIT0009], [@CIT0010]\]. In order to alleviate both morbidity and mortality associated with TB in PLWH, active case finding (ACF) for TB has been recommended as a strategy for regions with high TB and HIV incidence \[[@CIT0007], [@CIT0011]\]. Although the World Health Organization (WHO) recommends a symptom-based screening strategy for TB in PLWH as an essential component of HIV care, it has been shown to have low accuracy in detecting active TB, especially in high-burden TB areas \[[@CIT0002], [@CIT0014], [@CIT0015]\]. In contrast, due to the prevalence of nonspecific, or lack of, TB symptoms in PLWH, ACF utilizing the Xpert MTB/RIF for all patients could potentially identify a significant number of missed cases \[[@CIT0004], [@CIT0012], [@CIT0014]\]. However, limited data currently exists on the potential success of ACF using the Xpert MTB/RIF in PLWH in EE, where TB burden remains high.

In this cross-sectional study conducted in the country of Georgia, we sought to determine whether the rapid molecular diagnostic test, Xpert MTB/RIF, would improve active pulmonary TB case finding in PLWH. Our primary aims included determining the prevalence of pulmonary TB among newly diagnosed HIV-infected patients utilizing Xpert MTB/RIF and culture testing and evaluating the yield of a WHO-recommended symptom-based screening approach versus testing all patients for active TB. The overall goal of this research is to identify ways to improve the diagnosis of TB and, thus, close the "detection" gap among PLWH in Georgia and other similar settings.

METHODS {#s1}
=======

Study Population and Setting {#s2}
----------------------------

This cross-sectional study was conducted at the Infectious Diseases, AIDS, and Clinical Immunology Research Center (IDACIRC) and the National Center for Tuberculosis and Lung Disease (NCTLD) in Tbilisi, Georgia. IDACIRC is the national reference center for HIV diagnosis and treatment and provides care to approximately 65% of all HIV patients in the country. All newly diagnosed adult (≥18 years) HIV patients who presented for clinical care to the IDACIRC from February 2014 through May 2015 were eligible for enrollment. Receipt of anti-TB medications in the prior 60 days was an exclusion criterion. Ethics approval was obtained from the institutional review boards of IDACIRC, NCTLD, and Emory University, and written informed consent was required for participation.

Sample Collection and Laboratory Analysis {#s3}
-----------------------------------------

All study participants were asked to submit 2 sputum samples, including a spot and morning sample for analysis. A portion of obtained sputum samples underwent Xpert TB/RIF testing at the onsite IDACIRC laboratory, while the remaining portion (minimum of 2 ml) was transported to the NCTLD National Reference Laboratory (NRL) for AFB sputum smear microscopy and culture. At the NRL, all sputum samples were decontaminated and centrifuged before Ziehl-Nielsen staining for microscopy and inoculation onto solid egg-based Löwenstein--Jensen media for culture as previously described \[[@CIT0016]\]. *Mycobacterium tuberculosis* was confirmed by the use of the MTBDR*plus* assay (Hain Lifescience GmbH, Nehren, Germany). First-line drug susceptibility testing was carried out for all positive cultures as previously described \[[@CIT0016]\].

Data Collection and Analysis {#s4}
----------------------------

Study participants underwent a brief interview by routine clinical staff, who were also study collaborators to collect information on demographics, medical history, and the presence of pulmonary TB symptoms. Additionally, medical chart abstraction was carried out to collect similar information for HIV-infected patients hospitalized at the NCTLD hospital during the study period. All data was entered into an online REDCap database and analyses were performed with SAS, version 9.4 (Cary, NC). Study data were collected and managed using REDCap electronic data capture tools hosted at Emory University.

Our main outcome was the prevalence of pulmonary TB among newly diagnosed PLWH. A case of pulmonary TB was defined as either a positive sputum Xpert TB/RIF or positive culture for *M. tuberculosis*. We compared characteristics among HIV-infected patients with and without pulmonary TB and also evaluated the performance of the WHO symptom screen in detecting pulmonary TB. Additionally, we compared characteristics between HIV patients diagnosed with TB through our study (ACF) and HIV-infected patients who presented to the NCTLD with active TB during the study period (passive case finding). This comparison was undertaken to determine if TB was occurring at different stages of HIV infection in those who were diagnosed through active versus passive case finding. For all descriptive statistics, differences in categorical variables were tested using chi square test and for continuous variables a 2-sample *t* test. A *P* value \< .05 was considered significant.

RESULTS {#s5}
=======

A total of 276 newly diagnosed HIV-infected patients approached for study enrollment at the IDACIRC and 131 agreed to participate ([Figure 1](#F1){ref-type="fig"}). The median time from HIV diagnosis to study enrollment was 3 days (interquartile range 6--12). Among study participants, 103 of 131 (79%) were able to provide a sputum sample, and 15 (11.5% of those enrolled and 14.6% of those who provided a sputum sample) were found to have pulmonary TB. Among the 15 patients found to have pulmonary TB, 12 had a positive culture, 12 a positive Xpert TB/RIF assay, and 4 had a positive sputum smear microscopy ([Figure 2](#F2){ref-type="fig"}). All 4 patients with a positive sputum smear microscopy result had both a positive sputum culture and Xpert TB/RIF result. One patient each had multi-drug resistant (MDR) and isoniazid monoresistant disease, while the remaining 13 had drug-susceptible disease. The number of patients needed to test via ACF (utilizing Xpert MT/RIF and culture testing) to detect 1 case of pulmonary tuberculosis was 9 (131/15), and, if including only patients who submitted sputum samples, 7 (103/15).

![Flowchart of Patient Enrollment and Study Results](ofz233f0001){#F1}

![Venn Diagram, Sputum Xpert MTB/RIF, Culture and Microscopy Results Among HIV-Infected Patients Screened for Active Tuberculosis](ofz233f0002){#F2}

The majority of the 131 enrolled HIV-infected patients were male (70%), and the mean age of 42 years. There were high rates of alcohol (42%) and tobacco use (58%). Close to half of the patients (46%) had a positive HCV antibody test and the median CD4 count of those enrolled was 122 cells/mm^3^. At presentation and enrollment, 26% of the cohort had oral candida infection, 29% had presumed bacterial pneumonia, and 9% had a positive serum cryptococcal antigen test. Many of those enrolled (63%) had at least 1 of the following symptoms: cough, shortness of breath, night sweats, weight loss, or fever. Further characteristics are shown in [Table 1](#T1){ref-type="table"}. Patients with pulmonary TB were more likely to have a history of injection drug use (67% vs 36%, *P* = .02) and a positive HCV antibody test (73% vs 42%, *P* = .02) compared to patients without TB as well as higher rates of oral candida infection (60% vs 22%, *P* \< .01). Patients with pulmonary TB were significantly more likely to have cough, night sweats, weight loss, and fever than those without pulmonary TB (see [Table 1](#T1){ref-type="table"}). There was 1 death (7%) during TB treatment in our ACF group.

###### 

Characteristics of the HIV-Infected Patient Cohort Overall and by TB Status

  Demographics                          N = 131 (%)     Pulmonary TB Detected (n = 15)   No Pulmonary TB (n = 116)   *P*
  ------------------------------------- --------------- -------------------------------- --------------------------- -------
  Males                                 92 (70)         11 (73)                          81 (70)                     .78
  Mean age in years (SD)                42 (10)         42 (10)                          44 (12)                     .56
  Mean BMI \[kg/m^2^\] (SD)             22 (2.6)        21.4 (3.3)                       22.6 (2.5)                  .22
  Unemployed                            86 (66)         13 (87)                          73 (63)                     .07
  Prison history                        21 (16)         3 (20)                           18 (16)                     .66
  Current tobacco use                   76 (58)         10 (67)                          66 (57)                     .47
  Alcohol use                           55 (42)         6 (40)                           49 (42)                     .87
  Injection drug use                    52 (40)         10 (67)                          42 (36)                     .02
  Hepatitis C virus antibody positive   60 (46)         11 (73)                          49 (42)                     .02
  Prior TB treatment for active TB      4 (3)           0                                4 (4)                       .47
  HIV                                                                                                                
   Mean CD4 (SD)                        174 (184)       133 (146)                        179 (188)                   .28
   Median CD4 (IQR)                     122 (24--282)   79 (33--198)                     123 (21--295)               .61
  Presenting opportunistic infections                                                                                
   Oral thrush                          34 (26)         9 (60)                           25 (22)                     \<.01
   Cryptococcemia                       12 (9)          2 (13)                           10 (9)                      .55
   PCP pneumonia                        11 (8)          0                                11 (10)                     .36
   Bacterial pneumonia                  38 (29)         7 (47)                           31 (27)                     .11
  Symptoms at study enrollment                                                                                       
   Cough                                37 (28)         9 (60)                           28 (24)                     \<.01
   Shortness of breath                  15 (12)         3 (20)                           12 (10)                     .27
   Night sweats                         34 (26)         8 (53)                           26 (22)                     .01
   Weight loss                          57 (44)         11 (73)                          46 (40)                     .01
   Fever                                75 (57)         12 (80)                          63 (54)                     .01
    Temperature ≥ 38.0^○^C              64 (49)         12 (80)                          52 (45)                     .01
   ≥1 symptom                           83 (63)         14 (93)                          69 (60)                     .01

BMI indicates body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; PCP, pneumocystis pneumonia; SD, standard deviation; TB, tuberculosis.

The presence of any 1 symptom (fever, cough, weight loss, or night sweats) had a sensitivity of 93% in detecting patients with pulmonary TB and a negative predictive value of 98%. If only the 83 patients with at least 1 TB related symptom underwent diagnostic testing, 14 of 15 cases would have been detected and the number needed to test to detect 1 case would be 6. [Table 2](#T2){ref-type="table"} contains further performance characteristics of individual symptoms in detecting pulmonary TB.

###### 

Performance of Certain Signs and Symptoms in Detecting Patients With Pulmonary Tuberculosis

  Sign(s)/Symptoms(s)   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  --------------------- ----------------- ----------------- --------- ---------
  Fever                 80                46                16        95
  Cough                 60                76                24        94
  Weight loss           73                60                19        95
  Night sweats          53                78                24        93
  Any symptom           93^a^             41                17        98

^a^1 patient with tuberculosis had no symptoms; they were Xpert MTB/RIF and sputum culture positive for *M. tuberculosis.*

NPV indicates negative predictive value; PPV, positive predictive value.

During our study period, there were 28 HIV-infected patients who presented to the NCTLD with active TB. All patients were newly diagnosed with HIV after being diagnosed with TB. There were no significant differences among patients detected via our ACF study compared to HIV-infected patients presenting to the NCTLD with active TB in regards to age, gender, drug use, smear positivity, or CD4 count ([Table 3](#T3){ref-type="table"}).

###### 

Comparison of Selected Characteristics Between Confirmed Tuberculosis Among HIV-Infected Patients Diagnosed by Active and Passive Case Finding

                                  TB Diagnosed via Active Case Finding   TB via Diagnosed Through Passive Case Finding   
  ------------------------------- -------------------------------------- ----------------------------------------------- -----
  Mean age                        43.6                                   42.6                                            
  Male gender                     11 (73)                                23 (82)                                         .59
  Hepatitis C antibody positive   11 (73)                                16 (57)                                         .30
  Current tobacco user            10 (67)                                18 (65)                                         .88
  Alcohol use                     6 (40)                                 16 (57)                                         .28
  IDU                             10 (67)                                46 (46)                                         .21
  Prior TB treatment              0                                      3 (14)                                          .25
  Mean CD4                        133                                    147                                             .73
  Median CD4                      79                                     111                                             
  Sputum smear positive           4 (27)                                 9 (32)                                          .71
  Death                           1 (7)                                  4 (14)                                          .45

IDU indicates injection drug user; TB, tuberculosis.

Discussion {#s6}
==========

Utilizing an ACF strategy, we found a very high prevalence (11.5%) of pulmonary TB among all patients with newly diagnosed HIV who agreed to participate in our study in the country of Georgia. Our findings confirm TB/HIV coinfection as a major problem in Georgia and the utility of ACF as a strategy to enhance TB control activities. This is important to highlight and recognize given that Georgia and surrounding European and former Soviet Union countries are known more for their high rates of MDR and extensively drug-resistant TB with less attention given to TB/HIV coinfection. Our findings also highlight a high rate of HCV infection among persons with TB/HIV coinfection in Georgia. This is likely driven by high rates of injection drug use (67% among TB/HIV patients in our study), similar to what has been found in other surrounding former Soviet republics \[[@CIT0017]\]. Although our sample size was not powered to determine if a symptom-based screening strategy versus universal TB testing strategy was best among PLWH, we did find Xpert MTB/RIF testing was comparable to culture, thus confirming the effectiveness of an ACF strategy using molecular testing and supporting WHO recommendations on using Xpert MTB/RIF testing for the initial diagnostic work for TB among PLWH \[[@CIT0018]\].

According to the latest WHO TB report, the prevalence of HIV among incident TB cases worldwide is 9.2%; however, there is no detailed information included on the rate of active TB among patients with newly diagnosed HIV cases. Focusing only on the HIV prevalence rate among incident TB cases can mislead one into thinking TB/HIV coinfection is not a major problem in certain countries, such as Georgia. Prior data along with current national TB program data have found that only 1%--3% of incident TB cases in Georgia are coinfected with HIV, results that do not indicate TB/HIV as a major problem \[[@CIT0019]\]. However, our study, which focuses on a newly diagnosed HIV population that is much smaller than the number of incident TB cases per year in Georgia, clearly demonstrates the high burden of TB among HIV patients. Our TB prevalence rate (11.5%) was higher than the overall TB rate (5.8%) found in the meta-analyses by Getahun and colleagues, which included ACF studies that systematically included sputum samples from HIV-infected patients regardless of signs and symptoms. The 12 studies included \>9000 patients, all of whom were from countries in Southeast Asia or Sub-Saharan Africa \[[@CIT0020]\]. We could not find any published studies from EE or former Soviet Union countries utilizing a universal TB ACF among HIV-infected patients with which to compare our results. Along with prior data finding TB as the leading cause of death among HIV patients in Georgia \[[@CIT0021]\], our findings confirm that TB/HIV coinfection is a major problem in the country, and one that needs more attention, especially considering the 2-fold increase in HIV incidence during the last decade (18.1 new HIV cases per 100, 000 in 2016) \[[@CIT0022]\]. Given the late stage of HIV and high rates of injection drug use among our cohort, potential areas to target for TB prevention include earlier detection of HIV, harm-reduction strategies, and opiate substitution treatment for person using intravenous drugs \[[@CIT0023]\].

The WHO recommends ACF with a preliminary symptom screen followed by confirmatory testing to exclude TB among people living with HIV \[[@CIT0024]\]. This strategy has been limited in part by a low specificity of symptom screening leading to a large number needed to test and consequent laboratory burden \[[@CIT0003], [@CIT0025], [@CIT0026]\]. Our results found a comparable sensitivity (93%) and specificity (41%) of the WHO recommended symptom screen as compared to studies outside EE, and our study is one of the first studies providing data in the region \[[@CIT0003]\]. The low specificity of symptom screening for TB is far below the minimum proposed specificity requirement of 70% proposed by the WHO for a TB triage test \[[@CIT0027]\]. The low number of patients with any positive symptom needed to test to detect 1 TB case via Xpert MTB/RIF and culture testing makes a symptom screening strategy feasible to implement in Georgia. As expected in a cohort with paucibacillary disease, the Xpert MTB/RIF outperformed sputum microscopy in our cohort \[[@CIT0028], [@CIT0029]\] and performed similarly to solid culture.

We found similar demographics and severity of HIV disease among patients whose active TB was detected by either an active or passive case finding strategy. These results demonstrate a need to detect and treat HIV earlier as almost all patients in both cohorts presented with a CD4 count \< 200 cells/mm^3^. Given that initiation of antiretroviral therapy prevents TB, earlier detection and treatment of HIV is essential to decrease TB/HIV burden \[[@CIT0030], [@CIT0031]\]. The high rate of injection drug use present in both our active and passive TB cohorts is alarming. It presents challenges for care as injection drug use has been associated with poor linkage to HIV care in EE \[[@CIT0032]\], and it suggests that harm-reduction policies may be a potentially effective means to reduce HIV and, subsequently, TB \[[@CIT0023]\]. Addressing the injection drug use epidemic in Georgia and other EE countries is paramount to HIV, HCV, and TB control \[[@CIT0032], [@CIT0033]\]. Additionally, studies evaluating the yield and implementation challenges of screening persons infected with HCV or who use injection drugs for TB are needed. Finally, the prevalence of cryptococcemia in our cohort was high at 9%. Although TB is the leading cause of death among PLWH in Georgia, cryptococcal disease should not be neglected as it is a major cause of death among people living with HIV in Georgia and can occur simultaneously with TB \[[@CIT0008]\].

Our study is subject to several limitations. About half of those with newly diagnosed HIV infection who were approached for the study declined to participate, and given that the characteristics of patients who refused participation are unknown, our results may not be generalizable to all HIV patients in Georgia. Assuming patients with symptoms were more likely to participate and that all persons not enrolled did not have TB, the estimated prevalence of pulmonary TB among all HIV-infected patients approached for enrollment would still be high at 5.4% (15 out of 276). In addition, 21% of those enrolled in the study were unable to produce a sputum sample. The inability of some participants to provide a sputum sample reflects real world practice and speaks to the need for the development of nonsputum-based diagnostic tests, such as the urine lipoarabinomannan for TB \[[@CIT0034]\]. Collecting sputum samples allowed us to diagnose pulmonary TB only; thus, we likely underestimated the overall prevalence of TB given that extrapulmonary disease is common among PLWH \[[@CIT0035]\]. Additionally, chest x-ray (CXR) information was not performed as part of this study and, thus, information was not available to evaluate and compare the value of radiography for TB case finding.

In summary, we found a very high prevalence of pulmonary TB (11.5%) among patients with newly diagnosed HIV in the country of Georgia by utilizing an ACF strategy. Our findings led to the implementation of a similar national strategy among HIV-infected patients in Georgia with all patients who have a positive symptom screen undergoing Xpert MTB/RIF testing and importantly highlight the need for more attention and research on the prevalence of TB and ACF strategies among HIV-infected patients in Georgia and surrounding countries.
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